LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Relay Therapeutics Inc

Închisă

SectorSănătate

3.56 0.56

Rezumat

Modificarea prețului

24h

Curent

Minim

3.49

Maxim

3.56

Indicatori cheie

By Trading Economics

Venit

6.7M

-70M

Vânzări

-7M

677K

Marjă de profit

-10,395.126

Angajați

197

EBITDA

8M

-77M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+263.84% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-21M

605M

Deschiderea anterioară

3

Închiderea anterioară

3.56

Sentimentul știrilor

By Acuity

50%

50%

172 / 372 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Relay Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 aug. 2025, 22:51 UTC

Câștiguri

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Rev $4.01B

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Adj EPS $1.84

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H EPS $1.82

27 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug. 2025, 23:39 UTC

Câștiguri

Correction to Nvidia Earnings Article -- WSJ

27 aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug. 2025, 22:58 UTC

Câștiguri

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug. 2025, 22:57 UTC

Câștiguri

South32 FY Free Cash Flow $192 Million

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Total Capital Expenditure $1.35 Billion

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug. 2025, 22:55 UTC

Câștiguri

South32 Net Cash $123 Million at June 30

27 aug. 2025, 22:54 UTC

Câștiguri

South32: Focused on Maintaining Strong Operating Momentum

27 aug. 2025, 22:53 UTC

Câștiguri

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug. 2025, 22:53 UTC

Câștiguri

South32 Extends Capital Management Program for 12 Months

27 aug. 2025, 22:52 UTC

Câștiguri

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug. 2025, 22:50 UTC

Câștiguri

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug. 2025, 22:50 UTC

Câștiguri

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug. 2025, 22:45 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug. 2025, 22:43 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug. 2025, 22:43 UTC

Câștiguri

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources Net Debt $123 Million at June 30

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparație

Modificare preț

Relay Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

263.84% sus

Prognoză pe 12 luni

Medie 12.88 USD  263.84%

Maxim 19 USD

Minim 4 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRelay Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

8

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.88 / 3.285Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

172 / 372 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.